Genocea Biosciences Inc. (NASDAQ:GNCA) has been given a consensus recommendation of “Buy” by the five brokerages that are presently covering the stock. One research analyst has rated the stock with a hold rating and four have issued a buy rating on the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $14.25.
A number of research analysts recently commented on GNCA shares. Piper Jaffray Cos. lowered their price target on Genocea Biosciences from $9.00 to $12.00 and set an “overweight” rating on the stock in a report on Thursday, September 29th. FBR & Co reissued a “buy” rating on shares of Genocea Biosciences in a report on Monday, August 8th. Zacks Investment Research cut Genocea Biosciences from a “hold” rating to a “sell” rating in a report on Wednesday, October 19th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $15.00 price target on shares of Genocea Biosciences in a report on Thursday, September 29th.
Genocea Biosciences (NASDAQ:GNCA) opened at 4.32 on Tuesday. The stock has a 50 day moving average of $3.95 and a 200 day moving average of $4.43. Genocea Biosciences has a one year low of $2.56 and a one year high of $8.07. The company’s market cap is $122.60 million.
Genocea Biosciences (NASDAQ:GNCA) last posted its quarterly earnings results on Thursday, November 3rd. The company reported ($0.45) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.44) by $0.01. Genocea Biosciences had a negative return on equity of 57.92% and a negative net margin of 5,121.17%. On average, analysts anticipate that Genocea Biosciences will post ($1.64) earnings per share for the current fiscal year.
Several hedge funds have recently modified their holdings of GNCA. Alpine Partners VI LLC purchased a new stake in shares of Genocea Biosciences during the second quarter valued at about $120,000. TFS Capital LLC purchased a new stake in shares of Genocea Biosciences during the second quarter valued at about $133,000. Dimensional Fund Advisors LP purchased a new stake in shares of Genocea Biosciences during the second quarter valued at about $143,000. Ameriprise Financial Inc. purchased a new stake in shares of Genocea Biosciences during the second quarter valued at about $156,000. Finally, Northern Trust Corp boosted its stake in shares of Genocea Biosciences by 24.3% in the third quarter. Northern Trust Corp now owns 34,636 shares of the company’s stock valued at $177,000 after buying an additional 6,763 shares during the period. 58.67% of the stock is currently owned by institutional investors and hedge funds.